As a result, the technology stands at a complicated intersection in the fight against a shifting climate. Breeding plants to ...

In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...

CRISPR-based tools can’t easily access the DNA in these organelles, but researchers are finding other ways in.

Two recent studies identified gene knockouts that may make CAR T-cell therapy more effective, but the next step is applying ...

If you have been staring at CRISPR Therapeutics stock lately, wondering whether it is time to buy, hold, or rethink your position, you are far from alone. Over the past week, the stock has surged 16.1 ...

LONDON, GREATER LONDON, UNITED KINGDOM, October 14, 2025 /EINPresswire.com/ -- What Is The Expected Cagr For The Rare Disease Genome Editing Market Through 2025? The market size of genome editing for ...

This report provides an in-depth analysis of the global single-cell biotherapeutics market, highlighting key trends, growth ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest ...

The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human ...

The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human immune system is still “mind-blowing” for molecular biologist Joshua Modell of ...

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 6.54% at $68.29. The stock trailed the S&P 500, which registered a daily gain of 1.56%. On the other hand, the Dow registered a gain ...